Background: Insulin receptors are widely expressed in the brain and may represent a
crossroad between metabolic and cognitive disorders. Although antipsychotics, such as …

Background: The second-generation antipsychotic drug olanzapine is an effective
pharmacological treatment for psychosis. However, use of the drug is commonly associated …

Atypical antipsychotics may “directly” influence glucose homeostasis, increasing risk of type
2 diabetes independently of changes in adiposity. Animal models suggest direct effects after …

The atypical antipsychotics (AAPs) have been associated with an increased risk of type 2
diabetes. While weight gain associated with AAPs is a risk factor for diabetes, preclinical …

Antipsychotic use is associated with an increased risk of type 2 diabetes. Recent work
suggests antipsychotics can induce insulin resistance immediately and independently of …

Some atypical antipsychotics have been linked to an increased propensity for weight gain
and metabolic disturbances, including type II diabetes. The objective of this study was to …

Hypothalamic detection of elevated circulating glucose triggers suppression of endogenous
glucose production (EGP) to maintain glucose homeostasis. Antipsychotics alleviate …

Atypical antipsychotic drugs such as Olanzapine induce weight gain and metabolic changes
associated with the development of type 2 diabetes. The mechanisms underlying the …

BACKGROUND: Second-generation antipsychotics (SGAs) increase the risk of type 2
diabetes. The mechanism is thought to center on drug-induced weight gain, which starts the …

Insulin action in the central nervous system is a major regulator of energy balance and
cognitive processes. The development of central insulin resistance is associated with …